Live Breaking News & Updates on Revolution multi sector fund
Stay updated with breaking news from Revolution multi sector fund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
How Genomics Is Improving Cancer Screening, Investing May 18, 2021 Cancer remains one of the leading causes of death around the world, but advancements in genomics are enhancing detection and screening capabilities. For investors, that puts the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) at the forefront of vital healthcare developments. Advancements in cancer screening are also part of the broader sustainable investing conversation, indicating the ARK exchange traded fund could check that box for investors too. The early diagnosis of cancer can dramatically improve patient outcomes. “If diagnosed early, cancer often is manageable. In the US, more than 80% of the deaths occur in patients whose cancer already has metastasized prior to the diagnosis,” writes ARK Invest Director of Research Brett Winton. “Researchers estimate that blood tests that diagnose early-stage cancer could reduce the overall cancer mortality rate by more than 25%.”
Is This Ark Invest ETF a Sustainable Investing Play? The words impact investing typically bring to mind strategies that allocate funds to reflect strong environmental principles. What they often miss is the intersection of disruptive technology with sustainable investing principles. Perhaps surprising to some is that the intersection includes genomics, making the Noting that healthy economic growth is one of the core tenants of sustainability, genomics is positioned as a prime play on a new era of investing. “We believe that historians will deem this era as one of unprecedented technological foment,” said ARK Investor Director of Research Brett Winton in a new report. “They will identify robotics, artificial intelligence, energy storage, DNA sequencing, and blockchain technology as transformative innovation platforms that entered critical inflection points during this decade.”
May 5, 2021 Within the fast-growing genomics universe, one of the more compelling themes is the evolution of gene therapies – a theme the Relative to passive genomics exchange traded funds, the actively managed ARKG can more rapidly adjust gene therapy exposure. For investors, that’s an exciting prospects because gene therapies are the epicenters of improving patient outcomes and, in some cases, cures. One way that ARKG fits into this equation is that more gene therapy research is indicating long-read sequencing could be a pivotal long-term solution. “Recently, scientists at the Franics Crick Institute used CRISPR Cas9 to edit embryos and found off-target edits, or unintended changes to the genome, in 16% of them. These off-target edits suggest that more detailed sequencing techniques, perhaps long read sequencing, will be necessary to ensure the safety of gene-editing,” according to a recent note from ARK Investment Management.
Genomics is a fast-growing, rapidly evolving industry and the ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is a prime example of an exchange traded fund that’s nimble enough to capture that evolution. ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring healthcare, agriculture, and pharmaceuticals in the process. Next generation sequencing (NGS), including long read DNA, is an example of an evolving frontier ARKG puts investors at the forefront of. “Now that the clinical community is capitalizing on their speed and scale, ARK believes that the shortcomings of SRS-generated data are becoming more obvious.
The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is a prime example of an exchange traded fund with lots of levers to pull. Since it’s an actively managed fund, it’s worth examining some of the stocks that could propel ARKG higher this year. ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring health care, agriculture, and pharmaceuticals in the process. In a recent CNBC interview, ARK analyst Simon Barnett highlighted some of the names that could power ARKG to the upside, including Adaptive Biotechnologies.
Cancer Detection Meets Portfolio Perfection: The ARKG ETF Early cancer detection is an emerging frontier for healthcare companies. The ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring health care, agriculture, and pharmaceuticals in the process. “The Federal Drug Administration (FDA) recently granted Bluestar Genomics, a private company, a Breakthrough Device Designation for its liquid biopsy-based pancreatic cancer screening test,” writes ARK analyst Simon Barnett. “Stanford University researchers focusing on precision epigenomics founded Bluestar Genomics. Unlike those from GRAIL and Exact Sciences (EXAS), Bluestar’s tests focus on a biomarker called 5-hydroxymethylcytosine or 5hmC. 5hmC signals an epigenetic change in the genome that could inform oncologists to the presence of cancer.”
The ARKG ETF: Genomics Exposure with a Twist The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) is obviously positioned as a genomics fund, but as an actively managed exchange traded fund, it can venture into other growth areas in the healthcare sector. That includes telemedicine, as highlighted by the fund’s significant exposure to Teledoc (NYSE: TDOC). ARKG includes companies that merge healthcare with technology to capitalize on the revolution in genomic sequencing. These companies try to better understand how biological information is collected, processed, and applied by reducing guesswork and enhancing precision, restructuring health care, agriculture, and pharmaceuticals in the process.
How ARKG's Genomics Will Personalize Cancer Treatment etftrends.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etftrends.com Daily Mail and Mail on Sunday newspapers.